Medical News

RSS

Tenet announces revisions to its outlook for 2009

Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.

14 Sep 2009

Volunteers need to undergo pilot exam in support of national certification

A call for participants has been issued in the process of establishing a national certification for medical interpreters. Building upon the work the IMIA started in the 1980s with the ultimate goal of certification, volunteers are now needed to undergo the final written exam pilot in support of national certification.

14 Sep 2009

Digital Pathology Association has another Gold Sponsor: Sunquest Information Systems

Sunquest Information Systems, Inc., a market leader in laboratory and diagnostic information systems, today announced that it is a Founding Gold Sponsor of the Digital Pathology Association (DPA), a non-profit organization committed to the advancement of digital pathology applications in healthcare. The goals of the DPA include supporting digital pathology education initiatives, defining best practices, influencing standards and interfaces, organizing an annual conference that addresses diverse needs within the industry, and more.

From Evident Corporation - Life Sciences 14 Sep 2009

Spinal implants market to grow in the coming years: iData Research

According to a new market research report by iData Research, the leading international authority in medical device, dental and pharmaceutical market research, the U.S. market for spinal motion preservation devices is estimated to reach $2.54 billion by 2015. The global market for minimally invasive surgery (MIS) is also estimated to see double digit growth, with these two segments driving the overall market for spinal implants, MIS and VCF devices.

14 Sep 2009

Genoptix to present an overview of its specialized diagnostic laboratory services business

Genoptix, Inc., a specialized laboratory services provider, today announced the Company's participation at the following upcoming investor conferences.

14 Sep 2009

Phase 1 results of CTP-347 presented

Concert Pharmaceuticals, Inc. announced today the presentation of Phase 1 data on CTP-347, a deuterium-modified analog of paroxetine for the treatment of hot flashes. Concert presented the results during a poster session at the American College of Clinical Pharmacology’s 38th Annual Meeting.

14 Sep 2009

Sunlight Research's report analyzes Amgen EPO US patent portfolio

Sunlight Research((TM)) - The Source for Patent Analysis today announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio.

14 Sep 2009

Preliminary results of Phase 2b clinical trial of AZ-104 announced by Alexza Pharmaceuticals

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced preliminary results from its 366 patient Phase 2b clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache.

14 Sep 2009

Patheon declares third quarter 2009 results

Patheon (TSX: PTI) today announced results for the third quarter and nine months ended July 31, 2009. Total revenues for the third quarter were $164.4 million or 15.7% lower than the same period last year. Excluding currency fluctuations, current year third quarter revenues would have decreased by approximately 9.6%.

14 Sep 2009

Men and healthcare professionals urged to take proactive approach to prostate cancer

As prostate cancer is the third leading cause of cancer death in European men with more than 300,000 men being diagnosed every year, society needs to commit to changing the way the disease is viewed. Therefore a mini-symposium and lunch meeting are organized on 18 September 2009 in Antwerp on the occasion of the European launch of the Proactive Prostates Initiative, organized as part of Urology Week.

14 Sep 2009

ARIAD to complete its Phase 3 SUCCEED trial following DMS recommendation

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis as specified by the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to full patient enrollment and completion.

14 Sep 2009

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Celsion Corporation (NASDAQ:CLSN) and the American Liver Foundation (ALF) announced today that they have formed a partnership to provide education to physicians and liver patients about the treatment options for hepatocellular carcinoma (commonly referred to as primary liver cancer) and Celsion’s on-going ThermoDox Phase III global HEAT clinical study.

14 Sep 2009

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 and Phase 2a studies at the ERS Annual Congress in Vienna, Austria, September 12-16, 2009.

14 Sep 2009

Smith & Nephew's Endoscopy Division announces its inaugural fellowship meeting

Smith & Nephew's Endoscopy Division announced the kick-off of its inaugural fellowship meeting, The Wider Scope of Arthroscopy, at its global headquarters in Andover, Mass., starting today, Sept. 14 through Sept. 15. The event is also being supported by DJO, a leading global developer, manufacturer and distributor of high-quality medical devices that provide solutions for musculoskeletal health, vascular health and pain management.

14 Sep 2009

Gen-Probe to merge industrial testing assets into an independent company

Gen-Probe Incorporated announced today that it is spinning off its industrial testing assets into a new, independent company focused on developing rapid, highly accurate molecular assays for biopharmaceutical production, water and food safety testing, and other applications.

14 Sep 2009

DSG’s eCaseLink EDC software used in Cipher's Phase 3 dermatology study

DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne.

14 Sep 2009

CDI and VivoMedica launch pharmaceutical industry consortium

Cellular Dynamics International (CDI) and VivoMedica plc announce the launch of CARDIOTOX - a pharmaceutical industry consortium to validate a human cell model and analysis system for preclinical cardiotoxicity testing of pharmaceutical candidate compounds.

14 Sep 2009

Final results of SAPHRIS clinical study released

Schering-Plough Corporation today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study.

14 Sep 2009

GENova to file for Prostaganin patents in the US and in Europe

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

14 Sep 2009

New treatment center opened to overcome alcoholism

Michael Jackson. Heath Ledger. DJ AM. It seems that each new week brings news of another celebrity struck dead due to alleged drug abuse -- which represents only the tip of the iceberg of the epidemic of addiction. Our society is bombarded with advertisements hawking all varieties of alcohol and even prescription drugs -- but what can be done to stem the tragic growth of this disease?

14 Sep 2009